Landscape Capital Management L.L.C. Takes Position in Revolution Medicines, Inc. $RVMD

Landscape Capital Management L.L.C. purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 18,845 shares of the company’s stock, valued at approximately $1,501,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Revolution Medicines by 6.7% during the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock worth $1,331,739,000 after purchasing an additional 1,056,792 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Revolution Medicines by 194.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock worth $1,696,000 after purchasing an additional 14,062 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in Revolution Medicines during the 3rd quarter worth approximately $921,000. Mass General Brigham Inc purchased a new stake in Revolution Medicines during the 4th quarter worth approximately $27,407,000. Finally, M&T Bank Corp purchased a new stake in Revolution Medicines during the 4th quarter worth approximately $52,723,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on RVMD shares. Truist Financial started coverage on shares of Revolution Medicines in a research report on Monday, May 18th. They set a “buy” rating and a $179.00 target price on the stock. Guggenheim boosted their target price on shares of Revolution Medicines to $205.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Finally, Piper Sandler boosted their target price on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $123.72.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 120,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total value of $18,010,800.00. Following the sale, the insider owned 276,698 shares in the company, valued at $41,529,602.82. This represents a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is owned by insiders.

Revolution Medicines Stock Up 4.0%

NASDAQ:RVMD opened at $160.06 on Tuesday. The firm has a market capitalization of $34.03 billion, a P/E ratio of -22.64 and a beta of 1.40. Revolution Medicines, Inc. has a 1-year low of $34.00 and a 1-year high of $166.50. The company’s fifty day moving average price is $141.98 and its 200-day moving average price is $111.27. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period in the previous year, the business posted ($1.13) EPS. As a group, equities research analysts anticipate that Revolution Medicines, Inc. will post -7.94 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.